Overview

Lucentis for Macular Edema Associated With Central Retinal Vein Occlusion

Status:
Completed

Trial end date:
2013-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether ranibizumab (Lucentis) will be effective in reducing if not eliminating the macular edema associated with the disease, central retinal vein occlusion (CRVO).

Phase:

Phase 1

Details

Lead Sponsor:

California Retina Consultants

Collaborator:

Genentech, Inc.

Treatments:

Ranibizumab